Novo Nordisk AS's ROE % for the quarter that ended in Mar. 2026 was 97.24%. Novo Nordisk AS's PB Ratio for the quarter that ended in Mar. 2026 was 5.15.
Novo Nordisk AS's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 18.88%.
Novo Nordisk AS ROE % Adjusted to Book Value Related Terms
Novo Nordisk AS ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS ROE % Adjusted to Book Value Chart
MEX:NVON vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 18.88% mean?
Novo Nordisk AS (MEX:NVON) has a ROE % Adjusted to Book Value of 18.88% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's ROE % Adjusted to Book Value too high?
Novo Nordisk AS's current ROE % Adjusted to Book Value is 18.88%. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's ROE % Adjusted to Book Value compare to LLY and JNJ?
Novo Nordisk AS's ROE % Adjusted to Book Value of 18.88% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current ROE % Adjusted to Book Value is 18.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NVON) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.52, compared to a current price of MXN831.50 — trading 65.2% below its estimated fair value. The current ROE % Adjusted to Book Value is 18.88%. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NVON), the current ROE % Adjusted to Book Value is 18.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NVON) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN831.50 is trading 65.2% below its estimated GF Value™ of MXN2,387.52.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NVON:
ROE % Adjusted to Book Value: 18.88%
GF Value™: MXN2,387.52 vs. price of MXN831.50 (65.2% below fair value)
No single metric tells the full story. See the MEX:NVON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score
Get the complete analysis for MEX:NVON
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVON has been successfully added to your 
